Recommendations supporting respiratory syncytial virus vaccines marketed by Pfizer (NYSE:PFE) and GSK (NYSE:GSK) made last ...

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock ...

the safety concerns ultimately led Pfizer to stop further development of danuglipron. This is the second time that Pfizer has faced setbacks in connection with the pipeline development of danuglipron.

Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to ...

Pfizer recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in its share price over the past week. This move was primarily due to safety ...

Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the FDA, has been named to oversee the agency’s ...

Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...

Miní, a wild-born female jaguar, takes an unbelievable journey from the Iberá Wetlands to the Gran Chaco forest to revive a ...

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...